Literature DB >> 18288134

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

N Cambier, A Renneville, T Cazaentre, V Soenen, C Cossement, S Giraudier, N Grardel, J-L Laï, C Rose, C Preudhomme.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18288134     DOI： 10.1038/sj.leu.2405088

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.

Authors:  Wing-Yan Au; Thomas S K Wan; Edmond S K Ma
Journal:  Int J Hematol       Date:  2013-02-07       Impact factor: 2.490

2.  Imatinib and ruxolitinib association: first experience in two patients.

Authors:  Alessandra Iurlo; Umberto Gianelli; Davide Rapezzi; Daniele Cattaneo; Elisa Fermo; Francesca Binda; Elisa Santambrogio; Cristina Bucelli; Agostino Cortelezzi
Journal:  Haematologica       Date:  2014-03-14       Impact factor: 9.941

Review 3.  Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.

Authors:  Shinsuke Mizutani; Junya Kuroda; Daisuke Shimizu; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-02-11       Impact factor: 2.490

4.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

5.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

6.  Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.

Authors:  Gholamreza Toogeh; Shirin Ferdowsi; Fatemeh Naadali; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Reza Shirkoohi; Seyed H Ghaffari
Journal:  Med Oncol       Date:  2010-05-25       Impact factor: 3.064

7.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

8.  BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.

Authors:  Mihaela I Precup Cornea; Emmanuel Levrat; Paul Pugin; Daniel C Betticher
Journal:  J Med Case Rep       Date:  2015-04-08

9.  Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Authors:  A Zhou; E M Knoche; E K Engle; D A C Fisher; S T Oh
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

10.  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.